You are here

  • Home
  • Archive
  • Volume 3, Issue Suppl 1
  • CT-02 Features of patients screened for calibrate (rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis); hypogammaglobulinemia is frequent in patients with marked elevation of urinary protein

Article info

Article menu

Download PDFPDF

Clinical Trials
CT-02 Features of patients screened for calibrate (rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis); hypogammaglobulinemia is frequent in patients with marked elevation of urinary protein
Free

Authors

Citation

Aranow C, Diamond B, Wofsy D, et al
CT-02 Features of patients screened for calibrate (rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis); hypogammaglobulinemia is frequent in patients with marked elevation of urinary protein
Lupus Science & Medicine 2016;3:doi: 10.1136/lupus-2016-000179.74

Publication history

  • First published August 31, 2016.
Online issue publication 
September 01, 2016

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2016, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions